BACKGROUND: Pedunculopontine nucleus (PPN) stimulation is a novel therapy for Parkinson disease. However, controversies remain regarding the clinical application of this new therapy, including patient selection, electrode positioning, and how best to assess outcomes. OBJECTIVE: To clarify the clinical application of PPN stimulation in Parkinson disease. METHODS: Five consecutive patients with Parkinson disease complicated by severe gait freezing, postural instability, and frequent falls (all persisting even while the patient was on medication) received bilateral stimulation of the mid-lower PPN without costimulation of other brain targets. Outcomes were assessed prospectively over 2 years with gait-specific questionnaires and the Unified Parkinson Disease Rating Scale (part III). RESULTS: The primary outcome, the Gait and Falls Questionnaire score, improved significantly with stimulation. Benefits were maintained over 2 years. Unified Parkinson Disease Rating Scale (part III) items assessing gait and posture were relatively insensitive to these treatment effects. Beneficial effects often appeared to outlast stimulation for hours or longer. Thus, single-session on-vs off-stimulation assessments may be susceptible to ''delayed washout effects.'' Stimulation of the PPN did not change akinesia scores or dopaminergic medication requirements. CONCLUSION: Bilateral stimulation of the mid-lower PPN (more caudal than previous reports) without costimulation of other brain targets may be beneficial for the subgroup of patients with Parkinson disease who experience severe gait freezing and postural instability with frequent falls, which persist even while on medication. Choosing appropriate outcome measures and accounting for the possibility of prolonged stimulation washout effects appear to be important for detecting the clinical benefits.
P edunculopontine nucleus (PPN) stimulation is a novel therapy for Parkinson disease (PD). 1 In the nonhuman primate model of PD, low-frequency PPN stimulation mimicked local disinhibition and improved movement counts, posture, and balance. [2] [3] [4] Several small series have now reported that lowfrequency PPN stimulation in patients with PD appears to selectively improve freezing of gait (FOG), postural instability, and falls. [5] [6] [7] However, controversies remain regarding the clinical application of this new therapy, including patient selection, electrode positioning, and how best to assess outcomes. Consequently, the clinical utility and efficacy of PPN stimulation have been questioned.
In this study, we implanted bilateral PPN stimulators in 5 patients with PD complicated by severe FOG and frequent falls. Stimulation was delivered to the mid-lower PPN without costimulation of other brain targets. Outcomes were prospectively assessed over 2 years with validated gait-specific questionnaires and the Unified Parkinson Disease Rating Scale (UPDRS).
METHODS Participants
Five consecutive patients with PD (meeting UK Brain Bank Criteria) were implanted with bilateral PPN stimulators in Brisbane, Australia (Table) . Patients gave written informed consent.
It is currently unknown whether bilateral PPN stimulation is more beneficial than unilateral. The PPN has bilateral connectivity, perhaps suggesting that unilateral PPN stimulation may be sufficient. Other basal ganglia targets also have bilateral connectivity such as the subthalamic nucleus (STN). However, ipsilateral effects from STN stimulation are minimal and often temporary. 8 Additionally, in animal models, it is reported that activation of cholinergic projections from 1 PPN may cause inhibition of the other. 9 Given such theoretical uncertainties, we elected to implant and stimulate bilaterally.
The indication for PPN stimulation was severe FOG, postural instability, and falls that persisted even the patient was on medication. For these patients, freezing and falls, rather than motor fluctuations, were the predominant sources of morbidity. Patients were therefore implanted in the PPN only and did not, for example, receive costimulation of the STN.
Mean baseline characteristics were as follows: age, 69.4 years (SD, 5.6 years), disease duration, 11.0 years (5.7 years); UPDRS part III (UPDRS III, score/108) off/on medication, 36.6(9.8)/18.8(6.1); and Mini Mental State Examination (score/30), 28.8(1.1). Four patients were falling at least daily and 1 patient at least weekly.
Major cognitive and psychiatric impairment was excluded preoperatively by formal assessment with a neuropsychiatrist.
Surgery and Stimulation
The mid-lower PPN was targeted. The PPN region was located directly on 3-T T2 fluid-attenuated inversion-recovery magnetic resonance imaging (MRI) lateral to the superior cerebellar peduncle and its decussation, medial to the region of the medial lemniscus below the level of the inferior colliculus ( Figure 1 ). Trajectories passed through the subthalamic region into the PPN along its long axis. Dopaminergic medication was ceased the night before surgery. Stereotactic computed tomography computed tomography and MRI were volumetrically fused (Stealth, Medtronic). Electrodes (model 3387, Medtronic) were implanted with a CRW frame.
Microelectrode recordings were collected for later analysis but were not used to guide electrode placement. Awake intraoperative clinical assessments allowed stimulation side effects to be assessed (as described previously). 5, 6, 10 Beneficial effects of stimulation on gait and posture were not testable on the table.
Monopolar stimulation began at 35 Hz and 60 microseconds with titration of voltage. Choice of initial contact was based on results of postoperative imaging (aiming to stimulate the mid-lower PPN). The choice of frequency was based on early reports of PPN stimulation in humans. 7 Lower frequencies (including 10-Hz stimulation used in the primate experiments) were found to be less effective. 11 High-frequency stimulation at 130 Hz appeared to worsen motor function, including gait. Voltage was initially titrated on each electrode in turn, against bedside assessment of gait and postural stability, including the ''pull test'' for postural stability and turning on the spot for FOG. Both electrodes were then activated together, and comparisons were made between on vs off bilateral stimulation. Improvements in gait and postural control were often not immediately apparent, and titration sometimes required several visits over the course of a day or days. Similarly, turning off stimulation often did not result in acute rebound of gait and postural disturbance to prestimulation levels. We observed that this apparent prolonged effect of stimulation could sometimes last up to several days. Frequently, fine oscillopsia (as described previously) created a ceiling for voltages. 10 However, this could usually be overcome by slow voltage escalation over hours to weeks. All 5 patients experienced this oscillopsia, which we eventually regarded as a marker of correct stimulation location.
Assessments: Stimulation Location
Active contacts (monopolar cathodes) were identified on postoperative computed tomography fused with preoperative MRI and transformed onto Montreal Neurological Institute space with the fMRIB Software Library. 12 Coordinates were calculated in millimeters from midline (laterality), ventrodorsal distance (d) from the floor of the fourth ventricle, and rostrocaudal distance (h) from a pontomesencephalic (PM) line connecting the pontomesencephalic junction to the caudal end of the inferior colliculi (as described previously). 5 The relative location and extent of the PPN were based on reported choline-acetyltransferase immunohistochemical staining in humans. 13 
Assessments: Stimulation Clinical Effects
Questionnaires were prospectively administered preoperatively and 6 months and 2 years postoperatively (except for patient 2, who responded to the questionnaire preoperatively and postoperatively at 12 months and 2.5 years). These questionnaires assess function over the preceding weeks in patients' usual environments and medication states. The Gait and Falls Questionnaire (GFQ; score/64) assesses Parkinsonian gait disturbance, including FOG, festination, and falls. 14 The Freezing of Gait Questionnaire (FOGQ; score/24) and Falls Questionnaire (score/4) are components of the GFQ.
The UPDRS assessments occurred preoperatively and 2 years postoperatively (except for patient 2, who assessments occurred preoperatively and 2.5 years postoperatively), off and on both medication and simulation. Off-medication assessments were performed after overnight ($ 12 hours) withdrawal of dopaminergic medication. Onmedication assessments occurred in a ''practically defined on state'' after levodopa administration. 15 On/off-stimulation assessments occurred after a minimum 1-hour stimulation washout, a time period previously used by other studies investigating the effects of STN and PPN stimulation on gait and postural control. 5, 16 This 1-hour washout was also chosen to reflect what would be expected to occur realistically in routine clinical practice over a single visit. The UPDRS III was segmented into items 27 to 30 (IT27-30, score/16), assessing posture, gait, and balance, and items 1 to 26 (residual UPDRS, score/92), assessing bradykinesia, rigidity, and tremor. For all scales, higher scores indicate worse function. Clinical assessments were performed unblinded by neurologists specialized in movement disorders (W.T., P.S.).
Data Analysis
The primary end point was GFQ score, considered to best capture Parkinsonian gait disturbance in patients' usual environments and medication states. The GFQ scores were compared between time points with the Friedman test and post-hoc Wilcoxon signed-ranks test. Given that there were only 5 study participants, we have otherwise favored expressing individual outcomes rather than performing grouped statistical analysis. When we have compared means, the Wilcoxon signed-ranks test was used for rating scales and paired t tests for medication doses. Significance was set at P , .05. Statistical analysis was performed with the SPSS statistical package, version 19.0 (SPSS Inc, Chicago, Illinois).
RESULTS

Surgery and Stimulation
On immediate postoperative imaging, 1 electrode was found to be malpositioned too ventrally and was replaced 2 days after the initial surgery. There were no other surgical complications.
Positionings of the active contacts in 4 patients are presented in Figure 2 (imaging for 1 subject was missing).
Stimulation side effects were as described previously. 5, 6 At 2 years, stimulation parameters were monopolar 35 Hz, 60 microseconds, and mean 3.5 V (SD, 0.79 V).
Clinical Assessments
The GFQ scores for all 5 patients were improved at 6 months and 2 years compared with preoperatively ( Figure 3A) . Accordingly, the GFQ scores differed significantly between time points (x 2 = 7.60; P = .02) and were significantly better at 6 months (mean, 23.0 vs 47.2; Z = 22.023; P = .04) and 2 years (mean, 24.8 vs 47.2; Z = 22.023; P = .04) compared with preoperatively. The GFQ scores at 6 months and 2 years were not significantly different (23.0 vs 24.8; Z = 0.674; P = .50).
Similarly, FOGQ scores of all 5 patients were improved at 6 months and 2 years compared with preoperatively ( Figure 3B ). In 3 patients, improvements of FOGQ scores at 6 months were sustained or further improved at 2 years.
Patients reported fewer falls with PPN stimulation. In all patients, Falls Questionnaire scores at 6 months were improved compared with preoperatively ( Figure 3C ). Four of 5 patients (not patient 3) had improved Falls Questionnaire scores at 2 years compared with preoperatively.
Off-medication IT27-30 scores were improved in all patients when on stimulation at 2 years compared with preoperatively ( Figure 4A ). Intriguingly, off-medication IT27-30 scores at 2 years when off stimulation were also better than preoperatively in 4 patients despite washout periods of at least an hour. In only 2 patients at 2 years were off-medication IT27-30 scores better when on stimulation compared with off stimulation.
On-medication IT27-30 scores were improved in 3 patients when on stimulation at 2 years compared with preoperatively ( Figure 4B) . In 2 patients, on-medication IT27-30 scores at 2 years when off stimulation were better than preoperatively. In only 2 patients did ''on-medication'' IT27-30 scores at 2 years improve when on stimulation compared with off stimulation.
Residual UPDRS scores both off and on medication did not consistently change with stimulation in any patient. Residual UPDRS scores at 2 years on stimulation were not different from preoperative scores, either off medication (Z = 20.735; P = .46) or on medication (Z = 20.674; P = .50). Two years postoperatively, Residual UPDRS scores did not differ between on and off stimulation either off medication (mean, 25.2 vs 25.6; Z = 21.0, P = .32) or on medication (mean, 14.6 vs 14.6; Z = 0.0; P = 1.0). Dopaminergic medication requirements were not different at 2 years compared with preoperatively (mean, 1370 vs 1340 mg; t = 20.17; P = .87).
DISCUSSION
In 5 patients with PD complicated by severe and medically refractory FOG, postural instability, and falls, we found that PPN stimulation improved questionnaire scores measuring Parkinsonian gait and balance disturbance in patients' usual environments and medication states. Benefits persisted over 2 years. However, PPN stimulation did not improve UPDRS items assessing akinesia, rigidity, and tremor. Accordingly, dopaminergic medication requirements did not change.
We selected patients for PPN stimulation whose predominant symptomatic issues were severe FOG and postural instability persisting even while on medication and frequent falls, rather than motor fluctuations. In these patients, the therapeutic impact of PPN stimulation appeared substantial. However, this subgroup of patients is relatively uncommon. In 2 previous studies, patients were selected for PPN stimulation who had severe motor fluctuations requiring STN stimulation and variable degrees of gait disturbance. 5, 7 For example, some patients were selected for PPN stimulation to treat FOG that developed during STN stimulation. Other patients have been selected for PPN stimulation who had not experienced FOG that persisted on medication or recurrent falls. 5, 6 In such patients, the results of PPN stimulation have been disappointing. 5 Furthermore, it is possible that costimulation of the STN could influence the efficacy of PPN stimulation, particularly given their substantial reciprocal connections. 17 In this regard, it should be noted that the high frequencies required for STN stimulation (eg, 130 Hz) appear to worsen gait when delivered to the PPN.
The optimal site for PPN stimulation remains to be determined. Although the bulk of the PPN appears to be at the rostral level, cholinergic neurons are reported to be most numerous in the caudal PPN region. 17 Degeneration of cholinergic PPN neurons in parkinsonism has been associated with disturbances of gait and posture and with falls. 18, 19 We therefore targeted the mid-lower PPN, more caudal than previous reports in humans but similar to the target in the nonhuman primate by 2 of our investigators.
3,5 However, we acknowledge that the beneficial effects of stimulation cannot necessarily be attributed to the target itself but may, for example, reflect current spread to neighbouring nuclei or to afferent or efferent projections. 20 Outcome measures that are sensitive and practical will be needed for detecting the beneficial effects of PPN stimulation in routine clinical practice. For STN stimulation, it is usual to assess patients on and off stimulation at a single session with the UPDRS. However, such methods may be inappropriate for PPN stimulation. Indeed, we found that comparing IT27-30 scores on and off PPN stimulation during a single session with 1-hour washout periods was insensitive. One issue is that FOG is notorious for disappearing during medical assessments, possibly because of arousal mechanisms. 21 Consequently, any singlesession assessment of parkinsonian gait, even formal gait analysis, may not accurately reflect function in the patient's usual circumstances. 21, 22 Of further relevance is our finding that IT27-30 scores often did not rebound to preoperative levels on the cessation of stimulation for an hour. This may be due to a delayed washout effect of PPN stimulation, which, during titration, we observed could outlast stimulation for up to several days. This phenomenon has also recently been reported by others. 23 However, several previous studies of PPN stimulation have, like ours, used the IT27-30 with washout periods of # 1 hour, an approach our findings suggest may cause therapeutic effects to be underestimated. 5 Questionnaires have the advantage of reflecting function over prolonged periods and in patients' usual environments and medication states. The GFQ and FOGQ are specifically designed to assess parkinsonian gait disturbance and appeared sensitive to the impact of PPN stimulation. Ideally, however, an objective and ambulatory method to assess the effects of PPN stimulation would be preferable, the development of which may be informed by emerging evidence from gait analysis. 22 We acknowledge that our reliance on the Falls Questionnaire as the sole method of assessing falls frequency was not ideal. Falls diaries would likely have better captured this important end point.
CONCLUSION
Pedunculopontine nucleus stimulation is a novel treatment. We have performed a small prospective open-label study with unblinded outcome assessments. Our patient selection and specific PPN target differ from previous studies, and our findings suggest that bilateral stimulation of the mid-lower PPN without costimulation of the STN may be beneficial for the specific subgroup of PD patients who experience severe FOG, postural instability, and falls that persist even on medication. Choosing appropriate outcome measures and accounting for the possibility that therapeutic effects may persist long after PPN stimulation is switched off (delayed washout effects) appear to be important for accurately detecting therapeutic efficacy. These issues would be worth considering in the planning of any future randomized trial.
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